Bristol Myers Squibb Co said on Monday its combination therapy for multiple myel...
Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured at the headquarters in Le Passage, near Agen, France March 29, 2018. REUTERS/Regis Duvignau
- Bristol Myers Squibb Co said on Monday its combination therapy for multiple myeloma did not meet the main goal of showing an improvement in progression-free survival in newly diagnosed patients. The trial tested a combination of the company’s Empliciti, Celgene Corp’s Revlimid and a corticosteroid dexamethasone, against the combination of Revlimid and dexamethasone in a late-stage study.Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shinjini Ganguli
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Italy pledges 'massive shock therapy' to face coronavirus impactItalian Prime Minister Giuseppe Conte promised 'massive shock therapy'...
Les mer »
Gunfire breaks out at Cleveland party, leaving 1 dead, 17 wounded, police saidCleveland police say they learned that the party had “multiple motorcycle clubs' in attendance. The case has 'multiple shooters,' police said.
Les mer »
What is the 'flip the switch' challenge?The latest challenge comes from TikTok and has had multiple people creatively share their variation.
Les mer »
Taylor Hicks Details His 'Life and Death Experience' During Tennessee TornadoesThe American Idol winner was home in Nashville when multiple twisters ripped through the area.
Les mer »
North Korea fires three projectiles into sea, South Korea saysNorth Korea launches multiple short-range projectiles into sea, South Korea says via HeeShin sangmi_cha
Les mer »